AI assistant
Abliva Share Issue/Capital Change 2022
3131_rns_2022-07-13_190ed540-f8c1-4124-ac9b-9192a354a285.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, BELARUS, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS.
Last day of trading with BTA in Abliva
Abliva AB has carried out a rights issue where the subscription period ended June 27, 2022. The rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and the last day of trading in paid subscribed shares (BTA) is July 18, 2022. The record date is July 20, 2022, after which BTA is converted into shares as of July 22, 2022.
Advisors
Erik Penser Bank AB and Van Lanschot Kempen are financial advisors to Abliva and Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the share issue. Erik Penser Bank is the acting issuing agent in connection to the share issue. Baker & McKenzie Advokatbyrå KB is legal advisor to Erik Penser Bank AB and Van Lanschot Kempen.
For more information, please contact:
Catharina Johansson, Deputy CEO, CFO & VP Investor Relations +46 (0)46-275 62 21, [email protected]
Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) [email protected], www.abliva.com
Subscribe to our news: https://abliva.com/posts/news-subscription/ Follow us on LinkedIn:https://www.linkedin.com/company/abliva Subscribe to our YouTube channel: https://www.youtube.com/channel /UChqP7Ky5caXtp72CELhD6Mg
Abliva – Delivering mitochondrial health
Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
Press Release
Abliva AB (publ), 556595-6538 13 July 2022 13:20:00 CEST - Lund, Sweden
Important information
Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and persons in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, Russia, Belarus, the United States or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.